Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.
This case highlights the potential for long-term survival in PTTM associated with prostate cancer when treated promptly, although further research is needed to confirm these findings.
Where it sits
this study against the rest of the degarelix corpusSummary and findings
This case report discusses a 62-year-old man with pulmonary tumor thrombotic microangiopathy (PTTM) associated with untreated metastatic prostate cancer. The patient had an initial serum prostate-specific antigen level of 3,835 ng/mL and was treated with hormonal therapy, leading to rapid improvement in respiratory status. The patient has survived for over 10 years without recurrence of PTTM.
Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and often fatal pulmonary complication of malignancy, characterized by rapidly progressive pulmonary hypertension and difficulty in ante-mortem diagnosis. We report a case of PTTM associated with previously untreated metastatic prostate cancer in a 62-year-old man with an initial serum prostate-specific antigen level of 3,835 ng/mL and clinical stage cT3N0M1. <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed during the diagnostic workup revealed findings suggestive of pulmonary hypertension and right heart strain before the onset of overt respiratory failure. Shortly after prostate biopsy, the patient developed acute hypoxemic respiratory failure. Based on the clinical suspicion of PTTM, hormonal therapy was initiated promptly before pathological confirmation, resulting in rapid improvement of respiratory status. A definitive diagnosis of PTTM was subsequently established by pulmonary artery aspiration cytology obtained via right heart catheterization. The patient has remained alive for more than 10 years without recurrence of PTTM. This appears to represent the longest survival reported for PTTM to date. This case highlights the importance of early clinical suspicion and prompt cancer-directed therapy in patients with suspected PTTM.
Background
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare complication of malignancy that can lead to severe pulmonary hypertension and is often difficult to diagnose before death occurs. Prior knowledge indicates that PTTM is associated with various malignancies, including prostate cancer. This case report is significant as it presents a long-term survival outcome in a patient with PTTM, which is uncommon.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The report suggests that early clinical suspicion and timely hormonal therapy may improve outcomes in PTTM, although the evidence is based on a single case. The long survival of over 10 years is noteworthy but may not be generalizable due to the unique circumstances of the case. The lack of a control group and reliance on a single patient's experience limits the ability to draw broader conclusions.
Key findings
- Initial serum prostate-specific antigen level of 3,835 ng/mL.
- Patient has remained alive for more than 10 years without recurrence of PTTM.
Limitations
- Single case report, limiting generalizability.
- No control group for comparison.
- Not enough data on treatment specifics or outcomes.